Non-traumatic intracerebral hemorrhage (ICH) is one of the most devastating and disabling forms of stroke that account for 10--15% of all cases of stroke hospital admissions.^[@bib1],\ [@bib2],\ [@bib3]^ The average mortality rate was 50%, most of which occur during the first days after stroke. Among survivors, only an estimated 20% will regain functional independence at 6 months, whereas more than one-third of affected patients will not survive the first year.^[@bib1],\ [@bib3]^ Unfortunately, prediction of functional outcome that would assist in both preventive and therapeutic interventions remains elusive.^[@bib1],\ [@bib3]^

Functional outcome after ICH depends on the balance between brain injury and the activation of yet unknown compensatory response repairing the consequent damage.^[@bib4],\ [@bib5]^ Recent evidences indicate that strategies to enhance the response following brain injury provide promising opportunities to improve clinical outcomes and brain repair.^[@bib5]^ Then, to develop effective therapies that promote brain repair, we must have an understanding of the cellular and molecular events involved in the recovery from an ischemic insult.

The adult brain vascular system is stable under normal conditions and is activated in response to pathological conditions including injury.^[@bib6]^ Neovascularization following stroke is an essential compensatory response mediating brain repair, as it stimulates blood flow and metabolism in the damaged area^[@bib7],\ [@bib8]^ that activate other brain remodeling poststroke events leading to improved functional outcome of stroke patients.^[@bib9],\ [@bib10]^ Neovascularization requires new vessel formation from mature endothelial cells and immature CD34^+^ progenitor cells that includes endothelial progenitor cells (EPCs). These progenitor cells are mobilized from the bone marrow after vascular injury and home to the site of neovascularization, contributing to regeneration by either direct incorporation into newly forming vascular structures or indirectly via the secretion of proangiogenic growth factors, thereby enhancing the overall vascular recovery of ischemic brain.^[@bib11],\ [@bib12],\ [@bib13],\ [@bib14]^ Furthermore, emerging evidences confer to circulating EPC levels a prognostic value in the prediction of functional outcome in ischemic stroke^[@bib15],\ [@bib16],\ [@bib17]^ and ICH^[@bib18]^ patients.

The human *Tp53* gene harbors a common single-nucleotide polymorphism (SNP) at codon 72, which yields an arginine-to-proline amino-acidic substitution (*Tp53 Arg72Pro* SNP) that modulates the apoptotic activity of the tumor suppressor protein p53.^[@bib19],\ [@bib20],\ [@bib21],\ [@bib22]^ Previously, we found that the *Tp53 Arg72Pro* SNP controls neuronal susceptibility to ischemia-induced apoptosis *in vitro*.^[@bib23]^ In this study, we show that the *Tp53 Arg72Pro* SNP modulates endothelial cell survival after experimental ICH *in vivo*, which promotes EPC mobilization and neovascularization. Furthermore, functional recovery of patients after ICH is conditioned by the *Tp53 Arg72Pro* genotype. Our results thus reveal a novel function of the *Tp53 Arg72Pro* SNP in cerebrovascular repair and neurological outcome after stroke.

Results
=======

The *Tp53 Pro* allele is associated with high levels of circulating CD34^+^ cells and good functional prognosis after ICH
-------------------------------------------------------------------------------------------------------------------------

To assess whether the *Tp53 Arg72Pro* SNP is associated with long-term (12 months) prognosis after ICH, patients (see [Table 1](#tbl1){ref-type="table"} for baseline characteristics) were matched by functional outcome at discharge based on the modified Rankin scale (mRS) scores^[@bib24]^ ([Table 2](#tbl2){ref-type="table"}). We found that homozygous *Arg* allele patients (referred as Arg patients) with good outcome (mRS⩽2) at discharge suffered progressive disability (mRS\>2) after ICH. In contrast, patients harboring the *Pro* allele (referred as Pro patients) maintained a favorable outcome, even at long term after ICH ([Figure 1a](#fig1){ref-type="fig"}). Moreover, functional recovery was time-dependently improved in the Pro patients who had poor functional outcome (mRS\>2) at discharge, whereas it worsened in the Arg patients ([Figure 1b](#fig1){ref-type="fig"}). Interestingly, although the lesion volume on admission ([Figure 1c](#fig1){ref-type="fig"}) and perihematoma edema volume at 48--72 h following ICH ([Figure 1d](#fig1){ref-type="fig"}) were similar in both genotypes, indicating similar initial hemorrhagic damage, a fourfold lower residual cavity volume was observed in Pro patients at 6 months after ICH when compared with Arg patients ([Figure 1e](#fig1){ref-type="fig"}). Taken together, these results indicate that *Tp53-codon 72 Pro* allele-carrying subjects are protected against long-term poor functional outcome after ICH, whereas the homozygous *Arg* allele is associated to poor prognosis.

To understand the mechanism responsible for the long-term difference in prognosis of both alleles, we focused on neovascularization, a late-onset process that facilitates the neurogenesis, synaptogenesis and synaptic plasticity responsible for the long-term repair of the ischemic brain.^[@bib9]^ Neovascularization after cerebral ischemia is promoted by circulating CD34^+^ progenitor cells^[@bib11],\ [@bib13],\ [@bib14],\ [@bib25]^ and, although the mechanism is unknown, it correlates with functional outcome in ischemic stroke^[@bib15],\ [@bib16],\ [@bib17]^ and ICH^[@bib18]^ patients. We first corroborated this correlation in our ICH cohort ([Figure 2a](#fig2){ref-type="fig"}). Thus, levels of circulating CD34^+^ progenitor increased in patients with good functional outcome, whereas remained unchanged in those with poor prognosis ([Figure 2a](#fig2){ref-type="fig"}). To elucidate whether the *Tp53 Arg72Pro* SNP influenced neovascularization, we next matched patients by genotype and determined the levels of circulating CD34^+^ cells. As shown in [Figure 2b](#fig2){ref-type="fig"}, whilst levels of CD34^+^ cells at admission were similar in both genotypes, they significantly increased as soon as 7 days following ICH in Pro, but not in Arg patients. Interestingly, the patients showing the highest levels of CD34^+^ cells at 7 days after ICH corresponded with the Pro genotype and good prognosis (mR⩽2 at 3 months); in contrast, the patients with the lowest CD34^+^ levels were those of the Arg genotype and poor prognosis (mRS\>2 at 3 months) ([Figure 2c](#fig2){ref-type="fig"}). Flow cytometry analysis of the CD34^+^ progenitor cells revealed that the observed differences in CD34^+^ cell levels were not due to cell survival changes ([Figure 2d](#fig2){ref-type="fig"}). Next, we analyzed vascular endothelial growth factor (VEGF), angiopoietin-1 (Ang-1) and stromal cell-derived factor-1*α* (SDF-1*α*) for their known roles in the activation and mobilization of progenitor cells from the bone marrow in response to peripheral tissue hypoxia after stroke,^[@bib12],\ [@bib26]^ and migration of EPC to injured tissues^[@bib8],\ [@bib27]^ to promote neovascularization. Serum levels of VEGF ([Figure 1e](#fig1){ref-type="fig"}), Ang-1 ([Figure 1f](#fig1){ref-type="fig"}) and SDF-1*α* ([Figure 1g](#fig1){ref-type="fig"}) were significantly higher in Pro patients when compared with Arg patients, at 72 h after ICH. Altogether, these data indicate that the *Tp53 Arg72Pro* SNP determines the release of progenitor cell-activating factors and EPC mobilization from the bone marrow as a compensatory response to promote brain repair and functional recovery after ICH in humans.

The p53 Pro variant increases endothelial cell survival and triggers efficient EPC mobilization via VEGF and SDF-1*α* leading to neovascularization after experimental ICH
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------

To investigate directly the impact of the *Tp53 Arg72Pro* SNP on neovascularization after ICH, we next subjected humanized Tp53 knock-in (KI) mice models of both *Arg72Pro* codon variants^[@bib28]^ to a previously validated experimental ICH.^[@bib29]^ As shown in [Figures 3a and b](#fig3){ref-type="fig"}, the lesion volume observed at 6 h after experimental ICH was similar in both genotypes, indicating similar initial hemorrhagic insult; however, the time-dependent decrease in lesion volume was significantly faster in *Pro* than in *Arg* allele-carrying mice. Next, we evaluated functional recovery of mice after ICH by testing motor coordination and limb strength using the accelerated rotarod test.^[@bib30],\ [@bib31]^ Whereas at 24 h after ICH motor impairment was similar in both genotypes, mice expressing the Pro variant showed better motor performance than those with the Arg variant at both 48 h and 7 days after the hemorrhagic insult, which reflects a different level of functional recovery. Furthermore, mice carrying the *Pro* allele reached basal (before ICH) motor performance at 7 days after ICH; however, this effect was not observed in the *Arg* allele-carrying mice ([Figure 3c](#fig3){ref-type="fig"}), indicating poorer functional recovery than the Pro mice. All these findings confirm the results observed in humans ([Figure 1](#fig1){ref-type="fig"}), supporting that the humanized *Tp53 Arg72Pro* SNP KI mice variants functionally recapitulate the human phenotypes.

*In vivo* terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) staining revealed significantly less apoptotic cell death in the perihematoma area in the mice harboring the *Pro* allele than in those with the *Arg* allele ([Figure 3d](#fig3){ref-type="fig"}). Among the affected cells, we found not only neurons (TUNEL^+^ NeuN^+^ cells) ([Figure 3e](#fig3){ref-type="fig"}) but also endothelial cells (TUNEL^+^ CD31^+^ cells) ([Figure 3f](#fig3){ref-type="fig"}), which both underwent less apoptotic death in the Pro mice than in the Arg one. *In vitro* ischemia (oxygen and glucose deprivation) confirmed higher survival of cultured brain endothelial cells obtained from the Pro mice ([Figure 3g](#fig3){ref-type="fig"}). We therefore hypothesized whether endothelial cells\' survival against ICH dictated the production and release of angiogenic and EPC-mobilizing factors, including VEGF, Ang-1 and SDF-1*α* that led to the EPC mobilization, cerebrovascular repair and functional prognosis observed in patients ([Figures 1a](#fig1){ref-type="fig"} and [2e--g](#fig2){ref-type="fig"}). To test this, we measured circulating levels of CD34^+^ progenitor cells in both the *Tp53* Pro and Arg SNP variant KI mice after experimental ICH. In good agreement with the data observed in ICH patients ([Figure 2b](#fig2){ref-type="fig"}), the levels of CD34^+^ progenitor cells were significantly higher in the Pro mice when compared with the Arg one, 24 h after the insult ([Figure 4a](#fig4){ref-type="fig"}). Given that CD34 is not exclusively present in EPC, but also on mature endothelial cells -- although at a lower level -- specific EPC identification should be demonstrated by showing the presence of the endothelial marker VEGF receptor-2 (VEGFR2) and the absence of the pan-leukocyte marker CD45.^[@bib12],\ [@bib16],\ [@bib32],\ [@bib33]^ We therefore analyzed CD34^+^/VEGFR2^+^/CD45^−^ cells by FACS as a *bona fide* marker of EPC. As shown in [Figure 4b](#fig4){ref-type="fig"}, experimental ICH in the *Tp53 Arg72Pro* mice triggered a time-dependent increase in the circulating levels of EPC in the *Pro* allele-carrying mice, reaching the maximum level at 24 h after the insult; however, this effect was significantly attenuated in mice with the *Arg* allele ([Figure 4b](#fig4){ref-type="fig"}). Such difference was not because of a putative differential rate of EPC proliferation at the light of their same BrdU incorporation rate ([Figure 4c](#fig4){ref-type="fig"}) and cell cycle phase distribution ([Figure 4d](#fig4){ref-type="fig"}) in both genotypes. Furthermore, levels of EPC-mobilizing cytokines, VEGF ([Figure 4e](#fig4){ref-type="fig"}) and SDF-1*α* ([Figure 4f](#fig4){ref-type="fig"}), sharply increased in the Pro mice after the ICH insult, whereas this effect was significantly weakened in the Arg mice. Altogether, these results strongly suggest that the regulation of EPC mobilization by these cytokines dictates the different functional outcomes of the *Tp53 Pro* and *Arg* alleles in mice and patients after ICH.

As the ability of healthy endothelial to produce VEGF and SDF-1*α* has been estimated to be several weeks after the ischemic injury,^[@bib7]^ it is conceivable to propose that the high survival rate of endothelial cells in the *Pro* allele herein described is a key factor determining long-lasting production of growth factors and EPC mobilization after ICH. To ascertain whether the *Tp53 Arg72Pro* SNP determined cerebral neovascularization after ICH, brain sections of the KI mice were stained with the vascular endothelial cell marker isolectin-B4 (IB4), a well-known index of vascularization.^[@bib34]^ As IB4 also labels microglial cells,^[@bib34]^ we first used a combination of IB4 with the microglia-specific marker, Iba1. As shown in [Figure 5a](#fig5){ref-type="fig"}, we found microglial cells (IB4^+^/Iba1^+^ cells) in the perihematoma area in both Pro and Arg mice; however, microglia appears to locate around vessels in mice carrying the *Pro* allele, but not in those with the *Arg* one ([Figure 5b](#fig5){ref-type="fig"}), which may contribute to remove cell debris^[@bib10],\ [@bib35]^ and promote vascular repair.^[@bib36]^ In relation to morphology, we found that endothelial cells (IB4^+^/Iba1^−^ cells) form tubular structures, whereas microglia (IB4^+^/Iba1^+^ cells) exhibited a dendritic morphology in both Arg and Pro mice ([Figure 5](#fig5){ref-type="fig"}). Furthermore, IB4 staining is more pronounced in endothelial cells ([Figure 5a](#fig5){ref-type="fig"}). Therefore, IB4 labeling easily allows distinguishing microglial cells from endothelial cells, hence representing a suitable index of neovascularization as described previously.^[@bib34]^

We observed that experimental ICH induced a decrease in IB4 staining in the perihematoma area, 24 h after the insult in both *Pro* and *Arg* allele-carrying mice, suggesting brain blood vessel disruption with endothelial cell loss ([Figure 6a](#fig6){ref-type="fig"}). However, this effect was more pronounced in the Arg mice, in good agreement with the higher apoptotic endothelial cell death observed in this genotype ([Figure 6a](#fig6){ref-type="fig"}). Interestingly, the vascular density increased in the Pro mice 7 days after ICH, as revealed by the enhanced IB4 staining indicating vascular repair; however, this effect was significantly attenuated in the Arg mice ([Figure 6a](#fig6){ref-type="fig"}). We confirmed these observations using the endothelial cell marker, CD31 ([Figure 6b](#fig6){ref-type="fig"}). Neovascularization in the *Pro* allele-carrying mice was further confirmed as judged by the new IB4^+^/Iba1^−^ small vessels sprouting^[@bib34]^ from the existing vasculature ([Figure 7](#fig7){ref-type="fig"}). Our results thus demonstrate that vascular repair after ICH is mainly restricted to the *Pro* allele-carrying *Tp53 Arg72Pro* SNP.

Discussion
==========

During the recovery of the ischemic brain, oxygen and nutrient supply restoration is a critical process that requires the neovascularization of the affected area, where it stimulates the blood flow and metabolism^[@bib7],\ [@bib8]^ to induce poststroke brain remodeling and improved functional outcome.^[@bib9],\ [@bib10]^ In this study, we describe that the *Tp53 Arg72Pro* SNP dictates functional prognosis after ICH through a mechanism that involves endogenous bone marrow-derived EPC mobilization leading to neovascularization.

Delayed revascularization of postischemic brain tissue is known to be the main obstacle to preserve the brain function in stroke and ischemic retinopathies.^[@bib37],\ [@bib38]^ Here, we found that the patients harboring the *Arg* allele show delayed neovascularization, and poor functional outcome after ICH, when compared with the *Pro* allele carriers. Neovascularization not only augments cerebral flow,^[@bib7],\ [@bib8]^ but also migration of macrophages to the ischemic area to rapidly remove the necrotic debris.^[@bib10],\ [@bib35]^ Consequently, the increase in the number of newly formed vessels correlates with long-term survival of stroke patients.^[@bib10]^ Noticeably, our data show that the *Pro* allele is associated with increased neovascularization and good long-term functional outcome and survival after ICH.

Progenitor cell mobilization from the bone marrow occurs via the production and release of angiogenic factors, such as VEGF and Ang-1, in response to the peripheral tissue hypoxia after stroke.^[@bib12],\ [@bib26]^ Moreover, VEGF and the chemokine SDF-1*α* promote the migration and homing of EPC to the injured tissues, favor EPC differentiation and activate mature endothelial cells during neovascularization.^[@bib8],\ [@bib27]^ The higher levels of VEGF and SDF-1*α*, which we found after ICH in *Pro* allele-carrying patients, thus reflects an efficient mobilization and recruitment of CD34^+^ progenitor cells -- including EPC -- from the bone marrow to the sites of vascular injury. Besides its direct contribution to the formation of new vessels, recruited progenitor cells to the ischemic brain tissue may also remain in the interstitial space, whereby secreting cytokines and growth factors -- for example, SDF-1*α* and VEGF -- indirectly promote vascular repair via paracrine mechanisms.^[@bib12],\ [@bib26]^ In addition, it has been described that SDF-1*α*, released from infarcted brain tissue, together with EPC, operates as a chemotactic factor for the recruitment of additional EPC.^[@bib7],\ [@bib39]^ Our data are therefore consistent with the notion that this pathway is stimulated in the *Pro* allele patients leading to improved vascular repair, brain recovery and good functional prognosis after ICH.

To understand the mechanism responsible for the different postischemic neovascularization in *Arg* and *Pro* alleles, we focused on our previous data showing that the *Tp53 Arg72Pro* SNP modulates neuronal survival after ischemia *in vitro*,^[@bib23]^ which we now confirm *in vivo* (this work). Interestingly, besides neurons, the reduced vulnerability to ICH-induced apoptosis is also observed in the endothelial cells of *Pro* allele patients. Accordingly, healthier endothelial cells, such as those of the *Pro* patients, will likely produce more VEGF and SDF-1*α* for longer periods after ischemic injury as shown previously,^[@bib7]^ hence improving neovascularization. As the long-term prediction of functional outcome has remained elusive,^[@bib2]^ our results shed light on the long-term survival determinants of ICH patients.

In conclusion, here we show that different prognosis after ICH is dictated by the *Tp53 Arg72Pro* SNP through a mechanism that involves endogenous bone marrow-derived EPC mobilization leading to neovascularization, brain repair and improved functional prognosis after stroke. This study is the first in which the *Pro* allele of *Tp53* is linked to angiogenesis and ability to recover functionally from stroke. Thus, we propose that the *Tp53 Arg72Pro* SNP analysis should be used for the stratification of patients in clinical trials aimed to predict the functional prognosis after ICH. Furthermore, whether the mechanism herein described is also involved in the prognosis of other pathological conditions, such as cancer or chronic inflammation including retinopathies, is a likely possibility deserving further investigation. Therapies aimed to enhance the levels of cytokine-mediated EPC mobilization leading to neovascularization may be considered to improve the functional prognosis of *Arg*-allele-carrying ICH patients.

Material and Methods
====================

Patients
--------

Ninety-six consecutive patients with a first-ever primary non-traumatic ICH of \<12 h from symptoms onset and previously independent for their daily living activities were prospectively included in the study between March 2011 and February 2013. Patients with previously altered functional capacity (mRS⩾1) (*n*=4), chronic inflammatory diseases (*n*=3), severe hepatic (*n*=3) or renal (*n*=2) diseases, cancer (*n*=2) or infectious disease in the 15 days before inclusion (*n*=1) were excluded. Furthermore, three patients did not accept their participation in the study, thus a total of 78 patients (male, 69.2% mean age, 70.4±11.1 years) were finally included in the study.

This research was carried out in accordance with the Declaration of Helsinki of the World Medical Association (2008) and approved by the Ethics Committee of the Servizo Galego de Saúde. Informed consent was obtained from each patient or their relatives after full explanation of the procedures.

All patients were admitted to an acute stroke unit and treated according to the guidelines of the Cerebrovascular Diseases Study Group of the Spanish Society of Neurology.^[@bib40]^ Etiological diagnosis was made according the Guidelines for the management of spontaneous ICH in adults from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council and the Quality of Care and Outcomes in Research Interdisciplinary Working Group.^[@bib41]^ Medical history recording potential vascular risk factors, blood and coagulation tests, 12-lead ECG and chest radiography were performed at admission. To evaluate neurologic deficit, the National Institute of Health Stroke Scale (NIHSS) was performed at admission. Functional outcome was evaluated at discharge and at 3 and 12 months by using the mRS. NIHSS and mRS were evaluated by internationally certified neurologists.^[@bib23],\ [@bib24]^ The main outcome variable for all patients was considered poor functional prognosis (mRS\>2) at 3 months±15 days.

Antihypertensive treatment with intravenous labetalol or urapidil was administered in case of systolic blood pressure \>185 mm Hg or diastolic blood pressure \>105 mm Hg. Low-dose subcutaneous heparin was used for the prevention of deep vein thrombosis and pulmonary thromboembolism.

Neuroimaging studies
--------------------

Lesion volumes of the intracerebral hemorrhagic patients were determined by computed tomography (CT) scan using the formula 0.5 × *a* × *b* × *c*, where *a* and *b* represent the largest perpendicular diameters, and *c* represents the slice thickness. The hematoma volume was determined upon admission, and the perihematoma edema volume (total volume minus hematoma volume) in a second CT performed after 48--72 h. The residual cavity volume was determined with CT at 6 months±15 days. ICH topography was classified as lobar when it mainly affected the cortical or subcortical white matter of the cerebral lobes or as deep when it was limited to the internal capsule, the basal ganglia or thalamus. The presence of ventricular extension of the hematoma was also recorded. All neuroimaging evaluations were performed by neuroradiologists blinded to the patients\' clinical and laboratory results.

Human *Tp53* polymorphism analysis
----------------------------------

Genotyping of human *Tp53* polymorphism was performed at the University of Salamanca by authors blinded to the clinical status of patients, by using the PCR-RFLP technique.^[@bib23]^ The *Tp53* SNP of exon 4 at codon 72 (*Arg72Pro*; rs1042522) was detected by amplifying genomic DNA with the forward primer 5′-TCTACAGTCCCCCTTGCCGT-3′ and the reverse primer 5′-CTGACCGTGCAAGTCACAGA-3′. *Tp53* exon 4, where *Bst*U1 (Bsh1236I) RFLP is located, was amplified within a 298-bp DNA fragment. Digests were separated on agarose gel (3%) and the Midori Green Advanced-stained DNA fragments (Nippon Genetics Europe GmbH, Düren, Germany) were analyzed under a UV source (Gel Imager System; Bio-Rad, Hercules, CA, USA). The distribution of genotype frequencies in *Arg72Pro* between the ICH cohort was within the Hardy--Weinberg equilibrium (*P*\>0.1 in all cases). As the *Pro* allele is likely to exert a dominant effect on the *Arg* one,^[@bib23]^ two groups were considered for this study: Pro (*Pro/Pro* and *Pro/Arg* genotypes) and Arg (*Arg/Arg* genotype) patients.

Animals
-------

The humanized *Tp53 Arg72Pro* KI mice were generously donated by Prof. DG Johnson (The University of Texas MD Anderson Cancer Center, Smithville, TX, USA).^[@bib28]^ Animals were bred at the Animal Experimentation Service of the University of Salamanca, in accordance with Spanish legislation (RD 53/2013). Protocols were approved by the Bioethics Committee of the Institute of Biomedical Research of Salamanca. All efforts were made to minimize the number of animals used and ensure minimal suffering. All studies described below were conducted in a blind manner.

Experimental model of ICH
-------------------------

Experimental ICH was induced in 12-week-old mice by injecting bacterial collagenase VII from *Clostridium histolyticum* (purified by chromatography; Sigma, Madrid, Spain) into the basal ganglia.^[@bib29]^ Briefly, male mice under sevoflurane anesthesia (4% for induction and 3% for maintenance) evaporated in an oxygen--air mixture (30--70%) were placed in a stereotaxic frame (model no. 1900; Kopf, Tujunga, CA, USA) with a digital coordinate readout system (Wizard 550 Readouts; Anilam, Schaumburg, IL, USA). Collagenase (0.1 U in 0.5 *μ*l of saline) was injected unilaterally into the striatum using stereotactic coordinates: +0.9 mm anterior and +2.0 mm lateral to *bregma*, to a depth of 3.5 mm and at a rate of 0.1 *μ*l/min over 5 min. The needle stayed in place for additional 10 min to prevent reflux. During the procedure, rectal temperature was monitored (BAT-12 thermometer; Physitemp, Clifton, NJ, USA) and maintained at 37±0.5 °C. After the surgery, the animals were placed in a warm environment for recovering. Lesion volume was calculated from serial Nissl-stained sections of the mouse brains at 6 h and 1, 7 and 14 days after collagenase injection.

Accelerated rotarod test
------------------------

Performance based on motor coordination and limb strength in this test was assessed before (basal) and after ICH. Mice were trained for 3 days before ICH. All determinations were carried out at the same time every testing session by a researcher blind to the genotype. Mice were allowed to stay for 300 s on a five-lane accelerating rotarod (Model 47600; Ugo Basile, Comerio, Italy) rotating rod with a continuous accelerating rotation speed from 4 to 40 r.p.m., increasing 4 r.p.m. every 30 s and reaching the final speed at 270 s. The latency to fall off the rotarod was measured during this period, annotating the time the animal stayed on the rotation rod. Data from tests in which animals completed three turns without walking were disregarded.^[@bib42]^

Flow cytometry analysis of circulating progenitor cell levels
-------------------------------------------------------------

A 7 ml sample of EDTA venous blood was obtained from ICH patients at admission and day 7±1. Samples were processed within 1 h after collection by one researcher who had no knowledge of the patients\' clinical and radiological results. Mononuclear cells were isolated from peripheral blood by Ficoll density gradient centrifugation suspended in 100 ml of PBS. Immunofluorescence cell staining was performed in triplicate with the fluorescent conjugated antibody CD34-Fluorescein isothiocyanate (FITC; Becton Dickinson, Bergen, NJ, USA). IgG1-FITC antibody (Becton Dickinson) served as a negative control. Fluorescence was measured immediately after staining by flow cytometry (BD FACSAria IIu Becton Dickinson). Number of human CD34^+^ progenitor cells was expressed as absolute cell counts obtained after the measurement of 2.5 × 10^5^ events in the lymphocyte gate (FACS Diva software; BD Biosciences, Bergen, NJ, USA).^[@bib18]^ In some experiments, following CD34-FITC staining, cells were stained with annexin V-allophycocyanin (APC) and 7-aminoactinomycin D (7-AAD) in binding buffer (100 mM HEPES, 140 mM NaCl and 2.5 mM CaCl~2~). CD34^+^ progenitor cells (identified by FITC fluorescence) were analyzed, and the annexin V-APC-stained cells that were 7-AAD-negative were considered to be apoptotic.^[@bib23],\ [@bib43]^

In the *Arg72Pro* p53 KI mice, blood samples were collected in EDTA-coated microtainer tubes (Becton Dickinson) at 24 h before surgery (basal) and at different time points following experimental ICH. Immunofluorescence cell staining was performed in triplicate with the fluorescent conjugated antibodies CD34-FITC, VEGFR2-APC (eBioscience, San Diego, CA, USA) and CD45-phycoerythrin (PE; Immunostep, Salamanca, Spain). Cell fluorescence was measured immediately after staining by flow cytometry.^[@bib12]^ Percentage of CD34^+^/VEGFR2^+^/CD45^−^ cells was calculated using the CellQuest software (BD Biosciences).

Measurement of VEGF, Ang-1 and SDF-1*α* serum levels
----------------------------------------------------

Blood samples were obtained from ICH patients at 72±24 h following ICH, and from *Arg72Pro* p53 KI mice at different time points after collagenase injection. Samples were centrifuged at 3000 × *g* for 10 min and immediately frozen and stored at −80 °C. Serum levels of VEGF, Ang-1 and SDF-1*α* were measured using commercially available quantitative ELISA (enzyme-linked immunosorbent assay) Kits (VEGF and Ang-1 (R&D Systems Inc, Minneapolis, MN, USA) and SDF-1*α* (RayBiotech Inc., Norcross, GA, USA and Abcam, Cambridge, UK)).^[@bib18]^ Intra- and interassay coefficients were \<8% for all markers.

Cell cultures and treatments
----------------------------

Primary cultures of mouse brain capillary endothelial cell were prepared from cerebral cortices of 3-week-old *Arg72Pro* p53 KI mice.^[@bib44]^ Cortices were isolated, chopped in Dulbecco\'s modified Eagle\'s medium (DMEM), and homogenized with a serological pipette. Homogenates were cleaned from myelin using a 20% (w/v) BSA in DMEM and separated from erythrocytes by two centrifugations at 1000 × *g*, for 15 min. The resulting suspension was digested in 0.02 mg/ml collagenase/dispase (Roche, Heidelberg, Germany) in DMEM supplemented with 0.04 mg/ml DNase I (Roche), for 1 h at 37 °C in a shaking water bath. Cells were seeded on plastic plates coated with collagen I (BD Biosciences) and incubated in endothelial cell growth medium MV2 (Ready-to-use; Promocell, Birmingham, UK) supplemented with [L]{.smallcaps}-glutamine (Lonza, Barcelona, Spain) and 3 *μ*g/ml puromycin (Sigma). Brain endothelial cells were exposed to oxygen and glucose deprivation^[@bib45]^ and were stained with annexin V-APC and 7-AAD in binding buffer to determine quantitatively the percentage of apoptotic cells (V-APC^+^/7-AAD^−^) by flow cytometry.^[@bib23],\ [@bib43]^

For isolation of bone marrow progenitor cells from *Arg72Pro* p53 KI mice, whole bone marrow was collected from bilateral femurs and passed through a 40 *μ*m cell strainer (BD Falcon, BD Biosciences). Cells were then seeded on fibronectin-coated plates and cultured in RPMI-1640 medium (Sigma) supplemented with 10% (v/v) FBS. Cells were stained with CD34-FITC and BrdU incorporation and cell cycle phase distribution analysis were performed by flow cytometry, using the APC BrdU Flow Kit (BD Biosciences). BrdU^+^ cells and cell cycle distribution was measured immediately after staining in the CD34^+^ cell population, by flow cytometry.^[@bib43]^

Immunohistochemistry
--------------------

*Arg72Pro* p53 KI mice were anesthetized by intraperitoneal injection of a mixture (1:4) of xilacine hydrochloride (Bayer; Leverkusen, Germany) and ketamine hydrochloride/chlorbutol (Merial; Lyon, France), using 1 ml of the mixture per kg of body weight, and then perfused intra-aortically with 0.9% NaCl, followed by 5 ml/g per body weight of Somogy\'s fixative (4% p/v paraformaldehyde, 0.2% p/v picric acid in 0.1 M phosphate buffer, pH 7.4). After perfusion, brains were dissected out coronally in three parts and postfixed, using the Somogy\'s fixative, for overnight at 4 °C. Brain blocks were rinsed with 0.1 M phosphate buffer and sequentially immersed in 10%, 20% and 30% (w/v) sucrose in phosphate buffer until they sank. After cryoprotection, 20-*μ*m-thick coronal sections were obtained with a freezing-sliding cryostate (Leica CM 1950 AgProtect; Leica Microsystems, Wetzlar, Germany). Coronal sections were rinsed in 0.1 M PB three times each for 10 min and then incubated in (i) 1 : 250 anti-mouse CD31 (550274; BD Pharmingen, BD Biosciences), 1 : 200 anti-Iba1 (019-19741; Wako, Chemicals, Neuss, Germany), 1 : 1000 anti-NeuN (MAB377; Merck Millipore, Bellerica, MA, USA) or 1 : 50 anti-IB4 (L2140; Sigma) in 0.2% Triton X-100 (Sigma) and 5% goat serum (Jackson Immoresearch Laboratories, West Grove, PA, USA) for 72 h at 4 °°C in 0.1 M PB; (ii) fluorophore-conjugated secondary antibodies (Jackson Immunoresearch Laboratories) in 0.05% Triton X-100 and 2% goat serum in 0.1 M phosphate buffer, for 2 h at room temperature.^[@bib42]^ Nuclei were stained either with 6-diamidino-2-phenylindole (DAPI, blue fluorescence; Sigma D9542) or the commercial monomeric cyanine nucleic acid stain TO-PRO3 (far-red fluorescence; Molecular Probes T3605, Invitrogen) for 10 min. After rinsing with PBS, sections were mounted with Fluoromount (Sigma) aqueous mounting medium. Sections were examined with epifluorescence and appropriated filters sets using a microscope (Nikon Inverted microscope Eclipse Ti-E; Nikon, Tokyo, Japan) equipped with a precentered fiber illuminator (Nikon Intensilight C-HGFI, Tokyo, Japan) and B/W CCD digital camera (Hamamatsu; Tokyo, Japan), or with a spectral laser confocal microscope (Leica TSC-SL; Leica Microsystems) with three lasers: multiline Argon (488 nm), Helium-Neon (543 nm) and Helium-Neon (633 nm), and equipped with × 40, × 63 (1.4) HCX PL Apo oil immersion objectives for high-resolution imaging. Quantifications were performed in three regions of interest from three different sections per animal in an epifluorescence/light microscope (Nikon, Tokyo, Japan). Area occupied by CD31^+^ vessels was estimated by using the NIH image-processing package ImageJ (ImageJ 1.48v).

TUNEL assay
-----------

TUNEL assay was performed in brain sections following the manufacturer\'s protocol (Roche Diagnostics, Heidelberg, Germany). Brain sections, fixed as above, were preincubated in TUNEL buffer containing 1 mM CoCl~2~, 140 mM sodium cacodylate and 0.3% Triton X-100 in 30 mM Tris buffer, pH 7.2, for 30 min. After incubation at 37 °C with the TUNEL reaction mixture containing terminal deoxynucleotidyl transferase (800 /ml) and nucleotide mixture (1 *μ*M) for 90 min, sections were rinsed with PBS and counterstained with Cy3-streptavidin (Jackson Immunoresearch Laboratories).^[@bib42]^

Statistics
----------

Clinical results are expressed as either the mean±S.D. or median (25th and 75th percentiles) for the continuous variables depending on whether or not the data followed a normal distribution, respectively. The Kolmogorov--Smirnov test was used for testing the normality of the distribution. The Student\'s *t*-test (normal data) or the Mann--Whitney test (non-normal data) was used to compare continuous variables between two groups. Experimental results are expressed as mean±S.E.M. A one-way ANOVA with a least significant difference *post hoc* test was used to compare mean values between multiple groups, and a two-tailed, unpaired Student\'s *t*-test was used for two-group comparisons. In all instances, *P*\<0.05 were considered significant. Statistical analyses were performed using SPSS Statistics 22.0 for Macintosh (IBM, Madrid, Spain).
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![The *Tp53 Arg72Pro* SNP modulates long-term functional outcome after ICH. Patients were admitted at the University Clinical Hospital of Santiago de Compostela (Galicia, Spain). The study included 78 (*Arg/Arg*: 47, referred as Arg; *Arg/Pro* and *Pro/Pro*: 31, referred as Pro) patients with non-traumatic ICH. (**a** and **b**) Modified Rankin Scale (mRS) was used to evaluate the functional outcome of ICH patients. Patients were matched by (**a**) good (mRS⩽2) and (**b**) poor (mRS\>2) functional outcome at discharge and mRS scores were evaluated at 3 and 12 months after ICH with indicated *Tp53 Arg72Pro* genotypes. Boxplots show median values (horizontal line inside the box) and quartiles (box boundaries) (Mann--Whitney test). (**c**) Lesion volume on admission, (**d**) perihematoma edema volume at 48--72 h after ICH, and (**e**) residual lesion volume at 6 months after ICH were measured in patients with indicated *Tp53 Arg72Pro* genotypes. Data are mean±S.D. (Student\'s *t*-test). \*\**P*\<0.0001 versus Pro patients](cdd2016109f1){#fig1}

![The *Tp53 Arg72Pro* SNP dictates levels of circulating CD34^+^ progenitor cells after ICH. Patients were admitted at the University Clinical Hospital of Santiago de Compostela (Galicia, Spain). The study included 78 (*Arg/Arg*: 47, referred as Arg; *Arg/Pro* and *Pro/Pro*: 31, referred as Pro) patients with non-traumatic ICH. (**a**) Levels of circulating CD34^+^ progenitor cells in patients with good (mRS⩽2; 36 patients) and poor (mRS\>2; 42 patients) functional outcome at 3 months after ICH (one-way analysis of variance (ANOVA) followed by Bonferroni\'s test). (**b**) Patients were matched by genotype (Arg and Pro) and we studied circulating levels of CD34^+^ progenitor cells at 7 days after ICH in relation to mRS scores at 3 months after ICH. (**c**) Levels of circulating CD34^+^ progenitor cells in patients with indicated *Tp53 Arg72Pro* genotypes (one-way ANOVA followed by Bonferroni\'s test). (**d**) Apoptosis (annexin V-APC-stained cells that were 7-AAD-negative) were determined in CD34^+^ progenitor cells by flow cytometry at day 7 following ICH. (**g**--**i**) Serum levels of (**g**) VEGF (pg/ml), (**h**) Ang-1 (ng/ml) and (**i**) SDF-1*α* (ng/ml) at 72 h after ICH with indicated *Tp53 Arg72Pro* genotypes (Student\'s *t*-test). Data are mean±S.D. \**P*\<0.001; \*\**P*\<0.0001 *versus* (**a**) good functional outcome or (**b**--**g**) Pro patients](cdd2016109f2){#fig2}

![The Pro SNP variant promotes survival of cerebral endothelial cells and functional recovery following ICH. Humanized knock-in mouse model for both codon *Arg72Pro* variants of p53 (Pro and Arg) were subjected to experimental ICH. (**a**) Lesion volume (mm^3^) was measured on Nissl-stained histological sections from whole brain at indicated time points (one-way analysis of variance (ANOVA) followed by Bonferroni\'s test; *n*=4--5 mice per group). (**b**) Representative images of Nissl-stained histological sections from whole brain at indicated time points after ICH. (**c**) Rotarod testing was performed in mice before (basal) and at indicated time points after ICH. Latency to fall off the rotarod was recorded (one-way ANOVA followed by Bonferroni\'s test; *n*=4--5 mice per group). (**d**) Cell apoptosis were determined in the perihematoma brain region by TUNEL assay. Apoptotic cells were quantified as TUNEL (red)-positive cells per mm^2^ at 24 h following ICH (Student\'s *t*-test; *n*=4--5 mice per group). (**e**) Neuronal apoptosis were identified in perihematoma brain region by double staining with TUNEL (red) and neuronal marker NeuN (green) at 24 h after ICH (Student\'s *t*-test; *n*=4--5 mice per group). Representative images are shown. (**f**) Apoptotic endothelial cells were identified in perihematoma brain region by double staining with TUNEL (red) and endothelial cell marker CD31 (green) at 24 h after ICH. (**g**) Brain endothelial cells in primary culture were exposed to oxygen and glucose deprivation during 1, 3 and 6 h, and apoptosis were determined by flow cytometry (one-way ANOVA followed by Bonferroni\'s test; *n*=3 cell cultures per condition). Data are mean±S.E.M. \**P*\<0.05 *versus* Pro](cdd2016109f3){#fig3}

![The Pro SNP variant promotes efficient EPC mobilization via VEGF and SDF-1*α* following ICH. Humanized knock-in mouse model for both codon *Arg72Pro* variants of p53 (Pro and Arg) were subjected to experimental ICH. (**a**) Levels of circulating CD34^+^ progenitor cells were determined by flow cytometry at 24 h after experimental ICH. Data are mean±S.E.M. (Student\'s *t*-test; *n*=3 mice per group). (**b**) Levels of circulating CD34^+^/CD45^−^/VEGFR2^+^ cells were determined by flow cytometry at indicated time points after ICH. (**c** and **d**) CD34^+^ cells obtained from bone marrow of Pro and Arg mice were incubated during 3 h with BrdU (1 mM). (**c**) BrdU incorporation and (**d**) cell cycle distribution were determined by flow cytometry. Data are mean±S.E.M. (*n*=3 mice per group). Serum levels of (**e**) VEGF (pg/ml) and (**f**) SDF-1*α* (ng/ml) were measured at different time points after ICH (basal: 24 h before ICH). Data are mean±S.E.M. (one-way analysis of variance (ANOVA) followed by Bonferroni\'s test; *n*=4--6 mice per group). \**P*\<0.05 *versus* Pro](cdd2016109f4){#fig4}

![The Pro SNP variant promotes microglia localization around vessels after ICH. (**a** and **b**) Humanized knock-in mouse model for both codon *Arg72Pro* variants of p53 (Pro and Arg) were subjected to experimental ICH. Brain sections were costained with the vascular endothelial cell marker IB4 and the microglia-specific marker Iba1 at day 7 after experimental ICH. Nuclei were stained with the far-red fluorescent specific DNA dye TO-PRO3](cdd2016109f5){#fig5}

![Neovascularization after ICH is conditioned by the *Tp53 Arg72Pro* SNP. Humanized knock-in mouse model for both codon *Arg72Pro* variants of p53 (Pro and Arg) were subjected to experimental ICH. (**a**) Brain sections were stained with the vascular endothelial cell marker IB4 and the far-red fluorescent nuclear dye TO-PRO3 before and after 24 h and 7 days after ICH. (**b**) Brain sections were stained with the vascular endothelial cell marker CD31 at day 7 following experimental ICH. Green (CD31) fluorescence area per field was determined using the NIH ImageJ version 1.48 software (NIH, Bethesda, MD, USA). Data are mean±S.E.M. (Student\'s *t*-test; *n*=4 mice per group). \**P*\<0.05 *versus* Pro](cdd2016109f6){#fig6}

![The Pro SNP variant promotes vessel formation after ICH. Humanized knock-in mouse model carrying the Pro SNP variant of p53 were subjected to experimental ICH. Brain sections were costained with the vascular endothelial cell marker IB4 and the microglia-specific marker Iba1 at day 7 after experimental ICH. Nuclei were stained with the far-red fluorescent specific DNA dye TO-PRO3. White arrow indicates newly formed vessels](cdd2016109f7){#fig7}

###### Baseline demographic and clinical features of patients

  **Variables**                                  **ICH (*****n*****=78)**
  --------------------------------------------- --------------------------
  Age (years)                                           70.4±11.1
                                                             
  *Gender*                                      
   Females, *n* (%)                                     24 (30.8)
   Males, *n* (%)                                       54 (69.2)
  Time from ICH onset (h)                                5.1±3.7
                                                             
  *Diagnosis*                                   
   *Etiologic*                                  
    Hypertensive, *n* (%)                               36 (46.2)
    Amyloid, *n* (%)                                    26 (33.3)
    Anticoagulants, *n* (%)                              3 (3.8)
    Undetermined, *n* (%)                               13 (16.7)
   *Topographic*                                
    Deep, *n* (%)                                       48 (61.5)
    Lobar, *n* (%)                                      30 (38.5)
  Ventricular extension, *n* (%)                        23 (29.5)
  NIHSS on admission                                   10 \[5, 16\]
  Lesion volume on admission (ml)                       28.8±27.9
  Residual lesion volume at 6 months (ml)               11.7±17.7
  Poor prognosis at 3 months, *n* (%)                   42 (53.8)
                                                             
  *mRS at 3 months*                             
   0, *n* (%)                                           10 (12.8)
   1, *n* (%)                                           17 (21.8)
   2, *n* (%)                                            9 (11.5)
   3, *n* (%)                                           12 (15.9)
   4, *n* (%)                                            9 (11.5)
   5, *n* (%)                                            3 (3.8)
   6, *n* (%)                                           18 (23.1)
                                                             
  *Tp53 Arg72Pro SNP*                           
   Pro (*Arg/Pro*+*Pro/Pro*), *n* (%)                   31 (39.8)
   Arg (*Arg/Arg*), *n* (%)                             47 (60.2)
                                                             
  *Circulating CD34*^*+*^ *progenitor cells*    
   At admission, cells per 2.5 × 10^5^ events           203.9±90.7
   At day 7, cells per 2.5 × 10^5^ events              359.9±138.4

Abbreviations: ICH, intracerebral hemorrhage; mRS, modified Rankin Scale; NIHSS, National Institute of Health Stroke Scale; SNP, single-nucleotide polymorphism.

Patients were admitted at the University Hospital of Santiago de Compostela (Galicia, Spain). Data are shown as percentage (*n*, %), mean (S.D.) or medians (quartiles).

###### Modified Rankin Scale

  *Grade*   *Criteria*
  --------- -----------------------------------------------------------------------------------------------------------------------------
  0         No symptoms at all
  1         No significant disability: despite symptoms, able to carry out all usual duties and activities
  2         Slight disability: unable to perform all previous activities but able to look after own affairs without assistance
  3         Moderate disability: requiring some help but able to walk without assistance
  4         Moderately severe disability: unable to walk without assistance and unable to attend to own bodily needs without assistance
  5         Severe disability: bedridden, incontinent and requiring constant nursing care and attention
  6         Death

Modified from Banks and Marotta^[@bib24]^
